- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01008215
Simple Warfarin Dosing Algorithm Study (KT-INR)
Cluster Randomized Trial to Assess the Effect of Using a Simple Warfarin Maintenance Dosing Algorithm on the Quality of INR Control Among Canadian Family Practices
Can a simple and cost-free tool help family physicians to improve dosing of the blood thinner warfarin?
Warfarin is a blood thinner with a variable effect and requires regular blood monitoring and dose adjustments. Some family practices do not have the facilities or funding to use commercial tools than can assist with stabilizing the effect of warfarin. The investigators will test whether a simple and cost-free dosing tool can help these practices to improve warfarin management.
If this simple tool improves warfarin management, it will be freely available for practices in Canada and around the world. This will help physicians who have no access to more costly and/or complicated tools improve their warfarin dosing practice in a systematic fashion, and thereby maximize the health benefit of warfarin.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Burlington, Ontario, Canada, L7R 4C7
- Caroline Medical Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Family practices that:
- currently do not employ an evidence-based dosing method (anticoagulant clinic, computer system, manual algorithm or patient self-testing),
- manage warfarin maintenance dosing in at least 10 patients with target INR 2-3, and
- have at least one family physician providing written informed consent.
Patients who:
- are on long-term warfarin treatment (> 6 weeks before study entry and expected to continue for at least 6 more months) with target INR 2-3, for whom warfarin is managed by a participating family physician,
- patient provides written informed consent.
Exclusion Criteria:
Family practices that:
- are planning to start employing an evidence-based method for warfarin dosing within the next year,
- are not expected to enroll at least 10 patients on long-term warfarin treatment with target INR 2-3.
Patients:
- with < 3 months warfarin management prior to the baseline observation,
- patients on warfarin with a target INR other than 2-3, and
- patients for whom warfarin is managed by a physician who is not participating in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Algorithm
Algorithm (available in paper version and web-based version) will be used for warfarin maintenance dosing.
|
Warfarin Dosing algorithm (paper and electronic version)
|
|
No Intervention: Care as usual
Control group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mean time in therapeutic range for patients
Time Frame: 1 Year
|
1 Year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of patients with TTR > 65%
Time Frame: 1 Year
|
1 Year
|
|
Correlation between algorithm adherence and TTR
Time Frame: 1 Year
|
1 Year
|
|
Among patients in both baseline and study sample: proportion of patients with TTR improvement
Time Frame: 1 Year
|
1 Year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stuart Connolly, McMaster University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 09-282
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Warfarin Dosing
-
University of North Carolina, Chapel HillCompleted
-
NYU Langone HealthFood and Drug Administration (FDA)CompletedMedication Dosing ErrorUnited States
-
Vireo Systems, Inc.CompletedSafety of Short Term Creatine Hydrochloride DosingUnited States
-
Chinese University of Hong KongProfessor Bryan Ping Yen YAN (byan)Recruiting
-
University of AlbertaCompleted
-
University College CorkHoffmann-La Roche; Health Research Board, Ireland; ZyCare IncUnknown
-
Hacettepe UniversityCompletedModel Informed Precision DosingTurkey (Türkiye)
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of S- and R-warfarin | Pharmacodynamics of WarfarinUnited States
-
University of PennsylvaniaCompletedWarfarin and NSAIDUnited States
-
Celal Bayar UniversityCompletedWarfarin Knowledge Level | International Normalized Ratio Control | Patient TrainingTurkey
Clinical Trials on Algorithm
-
University of ArizonaWithdrawn
-
Samuel Lunenfeld Research Institute, Mount Sinai...Completed
-
University of California, San FranciscoEko Devices, Inc.CompletedAortic Valve Stenosis | Mitral Regurgitation | Heart Murmurs | Valvular Heart DiseaseUnited States
-
ResMedCompletedObstructive Sleep Apnea (OSA)Australia
-
ResMedRecruitingObstructive Sleep ApneaAustralia
-
Ottawa Heart Institute Research CorporationActive, not recruitingMitral RegurgitationCanada
-
Johann Wolfgang Goethe University HospitalHemoSonics LLCTerminatedHemorrhage | BleedingGermany
-
University of OxfordUnknownHeart Failure, SystolicUnited Kingdom
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Not yet recruitingModeling of Recruitment CurvesUnited States
-
ITALO EUGENIO SOUZA GADELHA DE ABREUCompletedDeep Vein Thrombosis | Artificial Intelligence | Clinical Decision Support Systems | Pulmonary Thromboembolisms | Superficial ThrombophlebitisBrazil